Tim F. Greten
Senior Investigator
Center for Cancer Research
National Cancer Institute
United States of America
Biography
Tim F. Greten, M.D., received his medical training at Christian Albrechts University in Kiel, Germany in 1993. He did his internship in Munich followed by a 3-year postdoctoral fellowship at the Johns Hopkins University (Baltimore, Maryland), in the laboratory of Drew Pardoll and Liz Jaffee, where he initiated his work in the field of tumor immunology. In 1999 Dr. Greten returned to Hannover Medical School, where he finished his training in internal medicine (2003), medical oncology (2004) and gastroenterology (2007). He held an associate professor position in the Department of Gastroenterology, Hepatology and Endocrinology. In February 2010 Dr. Greten joined CCR's Medical Oncology Branch as head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015. Dr. Greten has published more than 150 peer-reviewed papers on basic tumor immunology, translational research studies in hepatocellular carcinoma (HCC) as well as on clinical trials in different gastrointestinal malignancies, including HCC. Currently, Dr. Greten serves on the Center of Excellence in Immunology Steering Committee and Center for Advanced Preclinical Research oversight committee. He is a Chairperson of the CCR Scientific Protocol Review.
Research Interest
1) Gastrointestinal Cancer 2) Tumor immunology and Immunotherapy 3) Hepatocellular Carcinoma 4) Liver Immunology and Cancer 5) Preclinical and Translational Studies
Publications
-
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. Journal of hepatology. 2017 Mar 31;66(3):545-51.
-
Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer cell. 2016 Oct 10;30(4):533-47.
-
Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016 Mar 10;531(7593):253.
